FDA panel urges approval for Pfizer arthritis drug
An advisory committee to the US Food and Drug Administration on Wednesday urged US regulators to approve a new treatment for rheumatoid arthritis made by the pharmaceutical giant Pfizer.
Tofacitinib, taken orally, could serve as an alternative approach to treating moderate to severe patients who did not respond to one or more traditional therapies, said the advisory committee.
By a vote of 8-2, the panel urged the drug's approval despite mixed results on its effects at different doses, and some safety concerns about the risks of cancer -- mainly lymphoma -- and infections.
If approved by the FDA, it would be the first new oral disease-modifying drug for rheumatoid arthritis (RA) in more than 10 years and the first of its kind for RA in a new class of medicines called Janus kinase (JAK) inhibitors.
Rheumatoid arthritis is a progressive autoimmune disease that causes debilitating joint pain that can lead to deformity, and affects about 1.3 million Americans and 23.7 million people worldwide, most of them women.
Exactly what causes the disease remains a mystery, and there is no known cure.
According to Herb Baraf, clinical professor of medicine at George Washington University, the safety profile of tofacitinib is very similar to that of a relatively new class of drugs known as biologics.
"It decreases joint pain and swelling. It improves a patient's sense of well being. It decreases or eradicates morning stiffness," he told AFP.
"And at the 10 milligram dose it showed that it decreases the destructive nature of the arthritis. It slows down the progression of anatomic changes caused by rheumatoid arthritis."
Unlike biologics such as Humira which are injected, tofacitinib is taken in twice-daily pill form.
"To me, that is the biggest advantage," said Avram Goldberg, a rheumatologist at the North Shore-Long Island Jewish Health System.
Tofacitinib works differently than other treatments on the market because it inhibits signaling pathways inside the cells that lead to inflammation, Goldberg explained.
And since he estimates that 10-15 percent of his patients have not responded to available treatments, this may give them new hope.
"Not everybody responds to the drugs that are out there. So hopefully this will open up a new option for patients who haven't responded."
Two members of the panel voted "no" and one abstained on the question of whether the safety profile alone was adequate to support approval for the treatment of moderately to severely active RA in patients who have had inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate or leflunomide.
Those panelists said more data was needed to show whether there are safety issues over the long term.
Pfizer spokeswoman Kristen Neese said the company "appreciated the robust discussion."
She noted that data was presented on "approximately 4,800 tofacitinib-treated patients and one of the largest safety databases ever submitted to the FDA for a new drug application in RA."
"We believe the clinical trial results demonstrated a favorable benefit/risk profile and support the approval of tofacitinib," she added.
The FDA does not have to follow the recommendations of the advisory panel though it often does.
People who spoke during the public comment session at the FDA panel's meeting expressed support for the drug because it would offer patients another choice.
"This medication will improve the care of our patients who have severe rheumatoid arthritis," said Daniel Mandel, a doctor with the Coalition for State Rheumatology Organizations.
For Sharon Harris, a nurse who has experienced the pain of rheumatoid arthritis as part of her diagnosis of lupus, the disease caused "a paralyzing pain that literally took my breath away."
"What works for me may not work for my neighbor, and vice versa," she said.
(c) 2012 AFP
- Pfizer says patient died in oral RA drug study Apr 22, 2011 | not rated yet | 0
- New guidelines for treating rheumatoid arthritis Jul 22, 2008 | not rated yet | 0
- Anakinra for rheumatoid arthritis: A modest benefit with some risk Jan 21, 2009 | not rated yet | 0
- Antimalarial drug prevents diabetes in arthritis patients Oct 28, 2008 | not rated yet | 0
- Rheumatoid arthritis sends many into early retirement Feb 04, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Solvability of a circuit
3 hours ago Let's say I have a circuit consisting only of a finite number of batteries and resistors, all ideal. Given an arbitrary shape of this circuit, will I...
Question about perception of colors around light sources
7 hours ago When I look at a distant light source (like car headlights, or street lamp lights) I notice colors of the visible spectrum (as separated (as in after...
Does a charged particle rotate when traveling through a static Bf?
8 hours ago I have been looking at mass spectrometers, in particular the interactions between the Bf ind of a charged particle in motion in a static Bf of the...
Find a link between physics and assignment problems
10 hours ago Hi ! I've been working about assignments problems and how to solve them. I will have to do a presentation about it in few weeks. However, I'll...
Light as a source of electricity
10 hours ago Hello Dear Fellows! We all know that light is an electromagnetic wave and also we know that an antenna receives EM waves and...
A question about the energy stored in a capacitor.
10 hours ago If we imagine a simple circuit with a battery and a capacitor with negligible internal resistance, the capacitor is charged up to a point where the...
- More from Physics Forums - Classical Physics
More news stories
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
Arthritis & Rheumatism 10 hours ago | 4.8 / 5 (4) | 0 |
(HealthDay)—Compared to clinical diagnosis of synovitis, ultrasound-detected synovitis provides either improved sensitivity or specificity when used with the American College of Rheumatology/European League ...
Arthritis & Rheumatism May 15, 2013 | not rated yet | 0
(HealthDay)—A genome-wide linkage scan has identified the chromosome 17p11.2-q11.2 region as the susceptibility locus for fibromyalgia, according to research published in the April issue of Arthritis & ...
Arthritis & Rheumatism May 11, 2013 | not rated yet | 0
Scientists have discovered that fat cells in the knee secrete a protein linked to arthritis, a finding that paves the way for new gene therapies that could offer relief and mobility to millions worldwide.
Arthritis & Rheumatism May 08, 2013 | 5 / 5 (5) | 0 |
Researchers from the Royal College of Surgeons in Ireland (RCSI) have discovered that a new treatment for the inflammatory condition, Systemic Lupus Erythmstosus (SLE) could potentially benefit Irish patients who suffer from ...
Arthritis & Rheumatism May 07, 2013 | not rated yet | 0
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
9 hours ago | not rated yet | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
10 hours ago | 5 / 5 (2) | 0 |
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
9 hours ago | 5 / 5 (2) | 0 |
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
14 hours ago | not rated yet | 0
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
9 hours ago | not rated yet | 0
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...
22 hours ago | 4.8 / 5 (5) | 1 |